“…Monitoring of health-related quality of life (HRQoL) is done, for example, in childhood survivors who are treated for a pilocytic astrocytoma [9][10][11], low-grade glioma [12], high-grade glioma [13], craniopharyngioma [14,15], medulloblastoma [16,17], and in heterogeneous groups [18][19][20][21][22][23][24]. In most of these studies, survivors reported a variety of degree of reduction in HRQoL compared with healthy age mates [9,10,[13][14][15][16][18][19][20][21][22][23][24]. This could be explained by the heterogeneity of brain tumors and their treatments.…”